Outcomes After Surgical Resection of Early-stage Lung Adenocarcinomas With Epidermal Growth Factor Receptor Mutations

被引:5
作者
Chow, Oliver S.
Villena-Vargas, Jonathan
Nasar, Abu
Sun, Brian
Harrison, Sebron
Lee, Benjamin
Port, Jeffrey L.
Altorki, Nasser K.
Stiles, Brendon M.
机构
[1] New York Presbyterian Queens, Weill Cornell Med, Dept Cardiothorac Surg, New York, NY USA
[2] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Cardiothorac & Vasc Surg, Bronx, NY 10467 USA
关键词
CANCER; PLACEBO;
D O I
10.1016/j.athoracsur.2021.07.077
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Routine mutation profiling for resected lung cancers is not widespread despite an increasing array of targeted therapies. We report the incidence of epidermal growth factor receptor mutations (EGFRmu+) in resected lung adenocarcinomas and their outcomes at a large North American cancer center to characterize this population now eligible for targeted adjuvant therapy. METHODS Among 1036 pulmonary resections performed between 2015 and 2019, 647 patients (62%) had adeno-carcinomas that underwent molecular profiling by next-generation sequencing. Clinical and pathologic characteristics, along with survival, were analyzed. RESULTS EGFRmu+ were identified in 238 patients (37%). Patients with EGFRmu+ were more likely to be Asian than those with EGFR wild-type (79/238 [33%] vs 37/409 [9%], respectively; P < .001) and more likely to be never-smokers (115/238 [48%] vs 73/409 [18%], P < .001). However, most patients with EGFRmu+ in our cohort were White (45%) and had a history of smoking (52%). A statistically nonsignificant trend was observed toward improved 3-year overall survival for pathologic stage IB to III cancers with EGFRmu+ (91% vs 77%, P [ .09). Patients with pathologic stage IB lung cancers with EGFRmu+ had a 97% rate of 3-year disease-free survival, with only 1 recurrence in the first 3 years of follow-up. EGFR mutation subtype was not associated with survival differences. CONCLUSIONS Although Asians and never-smokers comprised a disproportionately large group of patients with lung adenocarcinomas with EGFRmu+, most EGFR mutations within our cohort were found in patients who were White or with a smoking history, supporting a routine rather than selective approach to mutation profiling. Patients with surgically resected stage IA and IB lung adenocarcinomas enjoy excellent survival regardless of their mutational status.(Ann Thorac Surg 2022;114:905-10)(c) 2022 by The Society of Thoracic Surgeons
引用
收藏
页码:905 / 910
页数:6
相关论文
共 15 条
[1]   Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial [J].
Altorki, Nasser K. ;
McGraw, Timothy E. ;
Borczuk, Alain C. ;
Saxena, Ashish ;
Port, Jeffrey L. ;
Stiles, Brendon M. ;
Lee, Benjamin E. ;
Sanfilippo, Nicholas J. ;
Scheff, Ronald J. ;
Pua, Bradley B. ;
Gruden, James F. ;
Christos, Paul J. ;
Spinelli, Cathy ;
Gakuria, Joyce ;
Uppal, Manik ;
Binder, Bhavneet ;
Elemento, Olivier ;
Ballman, Karla, V ;
Formenti, Silvia C. .
LANCET ONCOLOGY, 2021, 22 (06) :824-835
[2]   Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data [J].
Burdett, Sarah ;
Rydzewska, Larysa H. M. ;
Tierney, Jayne F. ;
Auperin, Anne ;
Le Pechoux, Cecile ;
Le Chevalier, Thierry ;
Pignon, Jean-Pierre .
LANCET, 2014, 383 (9928) :1561-1571
[3]   Gefitinib Versus Placebo in Completely Resected Non-Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study [J].
Goss, Glenwood D. ;
O'Callaghan, Chris ;
Lorimer, Ian ;
Tsao, Ming-Sound ;
Masters, Gregory A. ;
Jett, James ;
Edelman, Martin J. ;
Lilenbaum, Rogerio ;
Choy, Hak ;
Khuri, Fadlo ;
Pisters, Katherine ;
Gandara, David ;
Kernstine, Kemp ;
Butts, Charles ;
Noble, Jonathan ;
Hensing, Thomas A. ;
Rowland, Kendrith ;
Schiller, Joan ;
Ding, Keyue ;
Shepherd, Frances A. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) :3320-+
[4]   Worldwide Frequency of Commonly Detected EGFR Mutations [J].
Graham, Rondell P. ;
Treece, Amanda L. ;
Lindeman, Neal I. ;
Vasalos, Patricia ;
Shan, Mu ;
Jennings, Lawrence J. ;
Rimm, David L. .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2018, 142 (02) :163-167
[5]   Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition [J].
Hata, Aaron N. ;
Niederst, Matthew J. ;
Archibald, Hannah L. ;
Gomez-Caraballo, Maria ;
Siddiqui, Faria M. ;
Mulvey, Hillary E. ;
Maruvka, Yosef E. ;
Ji, Fei ;
Bhang, Hyo-eun C. ;
Radhakrishna, Viveksagar Krishnamurthy ;
Siravegna, Giulia ;
Hu, Haichuan ;
Raoof, Sana ;
Lockerman, Elizabeth ;
Kalsy, Anuj ;
Lee, Dana ;
Keating, Celina L. ;
Ruddy, David A. ;
Damon, Leah J. ;
Crystal, Adam S. ;
Costa, Carlotta ;
Piotrowska, Zofia ;
Bardelli, Alberto ;
Iafrate, Anthony J. ;
Sadreyev, Ruslan I. ;
Stegmeier, Frank ;
Getz, Gad ;
Sequist, Lecia V. ;
Faber, Anthony C. ;
Engelman, Jeffrey A. .
NATURE MEDICINE, 2016, 22 (03) :262-269
[6]   New and emerging targeted treatments in advanced non-small-cell lung cancer [J].
Hirsch, Fred R. ;
Suda, Kenichi ;
Wiens, Jacinta ;
Bunn, Paul A., Jr. .
LANCET, 2016, 388 (10048) :1012-1024
[7]   Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial [J].
Kelly, Karen ;
Altorki, Nasser K. ;
Eberhardt, Wilfried E. E. ;
O'Brien, Mary E. R. ;
Spigel, David R. ;
Crino, Lucio ;
Tsai, Chun-Ming ;
Kim, Joo-Hang ;
Cho, Eun Kyung ;
Hoffman, Philip C. ;
Orlov, Sergey V. ;
Serwatowski, Piotr ;
Wang, Jiuzhou ;
Foley, Margaret A. ;
Horan, Julie D. ;
Shepherd, Frances A. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) :4007-+
[8]  
Lindeman NI, 2018, J MOL DIAGN, V20, P129, DOI [10.1016/j.jmoldx.2017.11.004, 10.1016/j.jtho.2017.12.001, 10.5858/arpa.2017-0388-CP]
[9]   A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC [J].
Lisberg, A. ;
Cummings, A. ;
Goldman, J. W. ;
Bornazyan, K. ;
Reese, N. ;
Wang, T. ;
Coluzzi, P. ;
Ledezma, B. ;
Mendenhall, M. ;
Hunt, J. ;
Wolf, B. ;
Jones, B. ;
Madrigal, J. ;
Horton, J. ;
Spiegel, M. ;
Carroll, J. ;
Gukasyan, J. ;
Williams, T. ;
Sauer, L. ;
Wells, C. ;
Hardy, A. ;
Linares, P. ;
Lim, C. ;
Ma, L. ;
Adame, C. ;
Garon, Edward B. .
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) :1138-1145
[10]   EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China [J].
Pi, Can ;
Xu, Chong-Rui ;
Zhang, Ming-feng ;
Peng, Xiao-xiao ;
Wei, Xue-wu ;
Gao, Xing ;
Yan, Hong-Hong ;
Zhou, Qing .
THORACIC CANCER, 2018, 9 (07) :814-819